ArticleInternational journal of pharmaceutics: X2020

Xyloglucan based mucosal nanovaccine for immunological protection against brucellosis developed by supercritical fluid technology.

Swati Vyas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.